Exyte Partners with Univercells to Create Modular Vaccine Development Facilities
Exyte is partnering with Univercells Technologies to create modular biomanufacturing facilities to meet the increased global demand for vaccines during the SARS-CoV-2 pandemic. Exyte’s prefabricated construction system, ExyCell, is paired with Univercells’ NevoLine biomanufacturing platform which features the scale-X™ fixed-bed bioreactor at its core.